Pancreatic islet transplantation as a treatment for type 1 diabetes is limited by human donor tissue availability. We investigated whether the β-cell mass in human isolated islets could be expanded by treatments with glucagon-like peptide-1 (GLP-1) and gastrin, peptides reported to stimulate β-cell growth in mice and rats with deficits in β-cell mass. Human islets with low endocrine cell purity (7% β-cells, 4% α-cells) and abundant exocrine cells (29% duct cells and 25% acinar cells) were implanted under the renal capsule of nonobese diabetic-severe combined immune deficiency (NOD-scid) mice made diabetic with streptozotocin. The mice were treated with GLP-1 and gastrin, separately and together, daily for 5 weeks. Blood glucose was significantly reduced only in mice implanted with human pancreatic cells and treated with GLP-1 plus gastrin. Correction of hyperglycemia was accompanied by increased insulin content in the human pancreatic cell grafts as well as by increased plasma levels of human C-peptide in the mice. Immunocytochemical examination revealed a fourfold increase in insulin-positive cells in the human pancreatic cell grafts in GLP-1 plus gastrin-treated mice, and most of this increase was accounted for by the appearance of cytokeratin 19-positive pancreatic duct cells expressing insulin. We conclude that combination therapy with GLP-1 and gastrin expands the β-cell mass in human islets implanted in immunodeficient diabetic mice, largely from pancreatic duct cells associated with the islets, and this is sufficient to ameliorate hyperglycemia in the mice.
INTRODUCTION
cells and restores normoglycemia in alloxan-diabetic mice (22) . In addition, we recently reported that the combination of EGF and gastrin increased the β-cell mass in Transplantation of human pancreatic islets can replace insulin therapy in patients with type 1 diabetes adult human isolated islets, and this appeared to result from neogenesis of β-cells from pancreatic duct cells (25) but is limited by the scarcity of human donor pancreases and the frequent inadequacy of islet isolations present in the isolated islets (29) .
In the present study, we investigated whether the (26) . Recent studies suggest that pancreatic islet β-cells may be capable of proliferating and/or differentiating combination of GLP-1 and gastrin could expand the βcell mass in human isolated islets with low endocrine from precursor cells (2, 4) . Therefore, β-cell replacement therapies for type 1 diabetes might entail expansion of cell purity. GLP-1 was chosen to replace EGF in the combination with gastrin (29) because GLP-1 has been the donor β-cell mass to be transplanted by using one or more of recently reported β-cell putative growth factors.
reported to stimulate β-cell growth, in part by transactivation of the EGF receptor (6), but also via additional Many β-cell growth factors have been identified, including epidermal growth factor (EGF) and other EGF signaling pathways in β-cells (9). We report here that GLP-1 and gastrin combination therapy expanded the family members, such as transforming growth factor-α and betacellulin (8, 14, 15, 27, 36) . In addition, gastrointes-β-cell mass in human islets implanted in streptozotocin-diabetic immunodeficient mice, at least in part tinal peptides such as glucagon-like peptide-1 (30, 35) and gastrin (24, 32) can stimulate expansion of the β-cell from pancreatic duct cells associated with the islets, and this was sufficient to ameliorate hyperglycemia in mass. Combination therapy with EGF and gastrin induces islet regeneration from pancreatic exocrine duct the mice. 
MATERIALS AND METHODS
the left renal capsule of the diabetic mice according to a previously described procedure (31) . The mice were Human Islets housed and fed under specific pathogen-free conditions Human pancreases were obtained, with informed conin a biocontainment hood and were cared for according sent of relatives, from brain-dead organ donors. Tissue to the guidelines of the Canadian Council on Animal procurement and experimental protocols were approved Care. by the human ethics committee of the University of Alberta Hospitals. Pancreases were removed from donors GLP-1 and Gastrin Preparations after in situ vascular perfusion with the University of GLP-1(7-36)amide was purchased from Bachem (Tor-Wisconsin organ preservation solution, and islets were rance, CA). Gastrin was provided by Transition Theraisolated as previously described (16, 20) . Briefly, islets peutics, Inc. (Toronto, Canada). This gastrin is human were isolated by intraductal controlled perfusion and gastrin-17 synthesized and purified to greater than 97% digestion of the pancreas using an enzyme (Liberase huby HPLC; it has a leucine substitution for methionine at man islet, Roche, Laval, Canada) and by gentle mechanposition 15 to prevent oxidation and is equipotent to naical dissociation; then the islets were purified on contintive gastrin-17 (17). GLP-1 and gastrin were dissolved uous gradients of Ficoll-diatrizoic acid in a Cobe blood in sterile 100 mmol/L NaCl and 50 mmol/L NaPO 4 , pH cell processor (model 2991; Cobe Laboratories, Lake-7.4, at a concentration of 3 µg/ml, and were stored in wood, CO). Islets were provided by the University of aliquots at −70°C. Alberta distribution site of the Juvenile Diabetes Research Foundation Human Islet Distribution Program.
Experimental Studies Islet preparations with low endocrine cell purity (<20%
In the first study, the diabetic mice were divided into dithizone-stained cells) (33) were used in these studies.
two groups: one group was implanted with human pan-The islets were incubated in 5% CO 2 at 37°C for [18] [19] [20] [21] [22] [23] [24] creatic cells (3 × 10 6 ) from four different organ donors h in phenol red-free, serum-free, OptiMEM1 medium and the other group of mice was sham implanted. Mice containing 10 µg/ml insulin and 5 µg/ml transferrin (Inwith grafts from each donor and sham-implanted mice vitrogen Life Technologies, Inc.) plus 2 mmol/L L-glutawere subdivided into four groups that were treated with mine, 0.1 mmol/L sodium pyruvate, and 12 mmol/L PBS vehicle, 50 µg/kg GLP-1, 150 µg/kg gastrin, and HEPES (control medium).
50 µg/kg GLP-1 plus 150 µg/kg gastrin, given IP twice daily for 5 weeks. Tail vein blood glucose concentra-Islet Cell Preparations tions were measured in the nonfasting mice (at 1600-Islets were dissociated into single cells and small 1800 h) weekly, using glucose test strips and a meter clumps (≤5 cells) by incubation at 37°C for 10 min in (Glucometer Elite, Bayer, Etobicoke, Canada). At 5 an enzyme-free cell dissociation buffer (Invitrogen Life weeks, plasma was collected for human C-peptide assay, Technologies, Inc.) followed by syringe injection through the human pancreatic cell grafts were removed with a progressively narrower gauge needles (sizes 16-22). portion of underlying kidney for assay of insulin con-The cell composition of these islets with low endocrine tent, and the mice were killed. cell purity was determined by immunocytochemical
In the second study, diabetic mice were implanted staining (see Immunocytochemical Studies). This rewith human pancreatic cells (3 × 10 6 ) from one organ vealed that the islets contained 7 ± 2% insulin-positive donor and the mice were treated with the combination β-cells, 4 ± 1% glucagon-positive α-cells, 29 ± 3% cyof 50 µg/kg GLP-1 and 150 µg/kg gastrin given IP twice tokeratin-positive duct cells, and 24 ± 3% amylase-posidaily for 5 weeks. Blood glucose concentrations were tive acinar cells. Accordingly, cells obtained from these measured weekly. At 5 weeks the left kidneys with the isolated islets are referred to subsequently as "pancreatic human pancreatic cell grafts were removed from the ancells." esthetized mice. The mice recovered and blood glucose concentrations were measured daily until they exceeded Human Pancreatic Cell Implantations in Diabetic Mice 25 mmol/L; then the mice were killed.
In the third study, diabetic mice were implanted with Female nonobese NOD-scid/Lt mice, aged 6-8 weeks (The Jackson Laboratory, Bar Harbor, ME) were made human pancreatic cells (3 × 10 6 ) from four different organ donors, and the mice with grafts from each donor diabetic by administration of streptozotocin (STZ, Sigma-Aldrich Corp., St. Louis, MO) 190 mg/kg given IP.
were treated with either PBS vehicle or 50 µg/kg GLP-1 plus 150 µg/kg gastrin given IP twice daily for 5 Mice with blood glucose concentrations between 20 and 25 mmol/L within 3-5 days after STZ treatment were weeks. At 5 weeks the human pancreatic cell grafts were removed with a portion of underlying kidney from two used as recipients of human pancreatic cell implants. Human pancreatic cells (3 × 10 6 ) were implanted under mice of each treatment group for immunohistochemical study, and from four mice of each treatment group for diluted 1:400 (Vector Laboratories, Inc.), and then a streptavidin alkaline phosphatase conjugate (Zymed Labo-immunocytochemical study of cells dissociated from the grafts. ratories) and substrate kit (5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium, Vector Laboratories, Inc.).
Immunohistochemical Studies
CK19-positive pancreatic duct cells were identified on separate slides as well as on the same slides stained for The human pancreatic cell grafts were removed with a portion of underlying kidney, fixed in 10% buffered insulin-expressing cells by first blocking endogenous peroxidase activity using Peroxo-Block and BEAT formalin, embedded in paraffin, and sectioned at 4.5 µm. The sections were treated with Peroxo-Block and BEAT blocker kit (Zymed Laboratories), and then permeabilizing the cells with 3% saponin in PBS (Sigma-Aldrich blocker kit (Zymed Laboratories, South San Francisco, CA) to block endogenous peroxidase activity, and then Corp.). The cells were incubated with a mouse anti-human CK19 antibody diluted 1:15 (DakoCytomation) followed the cells were permeabilized with 3% saponin in PBS (Sigma-Aldrich Corp.). The sections were stained with by a biotinylated goat anti-mouse antibody diluted 1: 75 (DakoCytomation) and then a streptavidin peroxidase a guinea pig anti-insulin antibody diluted 1:200 (Dako-Cytomation, Carpinteria, CA), followed by a biotinyl-conjugate and substrate kit (3-amino-9-ethyl-carbazole, Zymed Laboratories). Glucagon-positive cells were ated goat anti-guinea pig antibody diluted 1:400 (Vector Laboratories Inc., Burlingame, CA), and then with a identified by incubation with a rabbit anti-human glucagon antibody diluted 1:10 (Biomeda, Foster City, CA), streptavidin peroxidase conjugate (Zymed Laboratories), followed by a substrate kit (3,3′-diaminobenzidine, Vec-followed by a biotinylated goat anti-rabbit antibody diluted 1:75 (Vector Laboratories, Inc.), then a streptavi-tor Laboratories, Inc.) that stained insulin-containing cells brown. Cytokeratin-19 (CK19)-positive pancreatic din alkaline phosphatase conjugate and substrate kit as was used for staining insulin-positive cells. Pancreatic duct cells were identified by incubation with a mouse anti-human CK19 antibody diluted 1:15 (DakoCytoma-acinar cells were identified by first blocking endogenous peroxidase activity (as above), and then incubation with tion), followed by a biotinylated goat anti-mouse antibody diluted 1:75 (DakoCytomation), and then a strep-a rabbit anti-α-amylase antibody diluted 1:50 (Biomeda), followed by a biotinylated goat-anti-rabbit anti-tavidin alkaline phosphatase conjugate and red substrate kit (Ventana Medical Systems, Tucson, AZ) that stained body diluted 1:75 (Vector Laboratories, Inc.), and a streptavidin peroxidase conjugate and substrate kit as CK19-positive duct cells red. Duct cells that expressed insulin (insulin + CK19 + ) were stained both brown (insulin + ) was used for staining CK19-positive cells. Finally, all slides were treated with a mounting medium (Crystal and red (CK19 + ). The sections were counterstained with crystal green.
Mount, Biomeda) and sealed with coverslips. A total of 2,000 cells in each of duplicate samples were scored Immunocytochemical Studies blindly by two independent observers using oil immersion ×100 magnification light microscopy. No cell stain-The cell composition of isolated islets before and after implantation in mice was determined by immuno-ing was seen in samples incubated with isotype control primary antibodies and the respective secondary anti-cytochemistry. The human pancreatic cell grafts were removed from the mice and dissociated into single cells bodies. using the enzyme-free cell dissociation buffer and the Insulin and C-Peptide Assays methods used to dissociate the original isolated islets. The graft cells were washed in PBS buffer, pH 7.4, then
Insulin in human pancreatic cell grafts was extracted by incubation in acidified ethanol (75% ethanol, 1.5% seeded onto glass slides coated with 3-aminopropyltriethoxysilane (Sigma-Aldrich Corp.) to attach the cells to 12 mmol/L HCl, and 23.5% H 2 O) for 18 h at 4°C. Ethanol extracts of cells were diluted in the insulin assay the slides. The cells were fixed with 4% paraformaldehyde in PBS for 1 h at 25°C, washed with PBS, and buffer. Insulin was measured by using an electrochemiluminescence immunoassay and the Elecsys 1010/2010 kept frozen at −86°C until immunostained. The slides were thawed and the cells were treated with 1% para-Modular Analytics E170 immunoassay analyzer (Roche, Mannheim, Germany). Human C-peptide in plasma of formaldehyde in PBS at 4°C for 10 min. One sample of cells on a slide was incubated with a specific antibody mice with human pancreatic cell grafts was measured by a RIA with no cross-reactivity to mouse C-peptide (e.g., to insulin or CK19) and another sample of the same cells on another slide was incubated with the cor-(Linco Research Inc., St. Charles, MO). responding isotype control antibody. Insulin-positive Statistics cells were identified by incubation with a guinea pig anti-insulin antibody diluted 1:200 (DakoCytomation), Data are presented as means ± SE. The significance of differences in mean blood glucose values between followed by a biotinylated goat anti-guinea pig antibody mice implanted with human pancreatic cells and sham-remained elevated (>20 mmol/L) in mice treated with GLP-1, gastrin, or GLP-1 plus gastrin and not implanted implanted mice (controls) was evaluated using the Mann-Whitney test. The significance of differences for with human cells, or even in mice implanted with human cells and treated with GLP-1 and gastrin, given sepa-all other mean values compared was evaluated using ANOVA with Dunnett's post test. Correlations between rately. By contrast, combination therapy with GLP-1 and gastrin significantly lowered blood glucose levels after plasma C-peptide concentrations and insulin content in cells, and between blood glucose concentrations and in-3-5 weeks of treatment in mice implanted with human pancreatic cells compared with the effects of GLP-1 plus sulin content in cells were evaluated by nonlinear regression ANOVA.
gastrin in sham-implanted mice. Severe hyperglycemia recurred in the GLP-1 plus gastrin-treated mice when kidneys bearing the human pancreatic cell grafts were RESULTS removed, indicating that the glucose-lowering effect of Blood Glucose Levels in Mice, and Insulin Secretion GLP-1 plus gastrin in the mice was related to function and Content of Human Pancreatic Cell Grafts of the human pancreatic cell grafts (Fig. 2) . In addition to the significantly decreased blood glucose levels in The effects of GLP-1, gastrin, and GLP-1 plus gastrin mice implanted with human pancreatic cells and treated on blood glucose levels in streptozotocin-diabetic NODwith GLP-1 and gastrin, plasma human C-peptide levels scid mice implanted with human pancreatic cells are in the mice and insulin contents in the human pancreatic shown in Figure 1 . Blood glucose levels in vehiclecell grafts were significantly increased compared with treated diabetic mice increased to very high levels (>25 vehicle-treated mice implanted with human pancreatic mmol/L), whether or not the mice were implanted with cells ( Fig. 3) . human pancreatic cells. Similarly, blood glucose levels compared with the graft in mice treated with vehicle ( Fig. 5A ). Extensive CK19-positive pancreatic duct cells were present in grafts in both vehicle and GLP-1 plus gastrin-treated mice. In addition, insulin-stained cells were seen in these grafts; however, more insulin-stained cells were present in grafts of GLP-1 plus gastrin-treated mice (Fig. 5D ) than in grafts of vehicle-treated mice (Fig. 5C ). Also, many of the insulin-stained cells in grafts of GLP-1 plus gastrin-treated mice expressed the 
Correlations of Glucose, C-Peptide, and Insulin
Blood glucose and plasma human C-peptide levels in mice that were treated for 5 weeks with vehicle, GLP-1, gastrin, and GLP-1 plus gastrin correlated significantly with insulin contents in the human pancreatic cell grafts in the mice. The positive correlation between plasma human C-peptide concentrations in the mice and insulin contents in the human pancreatic cell grafts was curvilinear, indicating that the first small increases in insulin content induced in the human pancreatic cell grafts by GLP-1 and/or gastrin resulted in the largest increases in plasma human C-peptide concentrations in the mice (Fig. 4A) . Similarly, the negative correlation between blood glucose concentrations in the mice and insulin contents in the human pancreatic cell grafts was curvilinear, indicating that the first small increases in insulin content induced in the human pancreatic cell grafts by GLP-1 and/or gastrin resulted in the largest decreases in blood glucose concentrations in the mice (Fig. 4B) . graft in mice treated with GLP-1 and gastrin (Fig. 5B)  Figure 4 . Correlations between the plasma human C-peptide concentration and the insulin content (A), and between the blood glucose concentration and the insulin content (B) in human pancreatic cell grafts in streptozotocin-diabetic NOD-scid mice at 5 weeks after the mice were treated IP twice daily with PBS vehicle (n = 7), 50 µg/kg GLP-1 (n = 7), 150 µg/kg gastrin (n = 8), and 50 µg/kg GLP-1 plus 150 µg/kg gastrin (n = 9). Nonlinear regression lines, correlation coefficients (r), and significance levels (p) are shown. CK19 duct cell marker (Fig. 5D ). The grafts were disso-2.5-fold in the human grafts from GLP-1 plus gastrintreated mice compared with the number of CK19-posi-ciated and their cell compositions were determined by immunocytochemical analysis (Fig. 6 ). This revealed tive cells initially implanted (20.1 ± 1.2 × 10 5 vs. 8.8 ± 2.1 × 10 5 cells). The numbers of CK19-positive duct that insulin-positive cells in the human grafts were increased fourfold in GLP-1 plus gastrin-treated mice cells that coexpressed insulin (insulin + CK19 + cells) in human grafts from GLP-1 plus gastrin-treated mice compared with the number of insulin-positive cells initially implanted (15.5 ± 1.1 × 10 5 vs. 3.7 ± 1.3 × 10 5 (10.6 ± 1.7 × 10 5 cells) was 53 ± 7% of the total number of CK 19-positive cells in these grafts (20.1 ± 1.2 × 10 5 cells). Also, CK19-positive duct cells were increased cells) and 68 ± 9% of the insulin-positive cells in the adult human pancreatic tissue. This was achieved by implanting human isolated islets of low β-cell purity, and grafts from GLP-1 plus gastrin-treated mice (15.5 ± 1.1 × 10 5 cells). The pancreatic CK19-positive duct cells ini-containing exocrine duct and acinar cells, into streptozotocin-diabetic immunodeficient mice, and then treating tially implanted in the mice did not express insulin and very few CK19-positive duct cells (7 ± 2%) expressed the mice with GLP-1 and gastrin. Immunohistochemical study revealed that pancreatic duct cells, identified by insulin in vehicle-treated mice.
GLP-1 Plus Gastrin Induces Insulin Expression
staining with the ductal cell marker, CK19, as well as DISCUSSION insulin-stained cells were significantly increased in the human pancreatic cell grafts implanted in the GLP-1 Successful transplantation of human pancreatic islets provides the prospect of a cure for type 1 diabetes; how-plus gastrin-treated mice. Approximately one half of the CK19-positive duct cells expressed insulin (insulin + ever, the lack of sufficient donor pancreases greatly limits the widespread use of this approach. The present CK19 + ), suggesting that at least part of the increase in insulin-positive cells induced by GLP-1 plus gastrin was study shows that the combination of GLP-1 and gastrin can substantially increase (fourfold) β-cell numbers in derived from CK19-positive duct cells. Definitive proof that the GLP-1 plus gastrin-induced increases in insulin-quent study, neogenesis of human islets in vitro was reported at least partly to represent the dedifferentiation of positive CK19-positive cells is evidence of β-cell neogenesis from duct cells, however, would require lineage islet cells into a CK19-positive duct cell-like phenotype, with further redifferentiation into islet endocrine cells tracing studies.
Plasma human C-peptide levels were significantly in-(10). In a more recent study of the potential for β-cell regeneration in the adult human pancreas, β-cells were creased and hyperglycemia was ameliorated in the mice implanted with human pancreatic cells and treated with found to differentiate from epithelial (duct and/or acinar) cells depleted of both endocrine and mesenchymal the combination of GLP-1 and gastrin. This suggests that the insulin-expressing cells induced by GLP-1 and cells (13). Insulin-positive cells were derived from the nonendocrine pancreatic epithelial cells and there was gastrin were capable of insulin secretory function in response to glucose stimulation. Interestingly, the first no evidence of β-cell replication. Interestingly, β-cell neogenesis was induced by implanting the adult human small increases in insulin content in the human pancreatic cell grafts in the mice led to the largest increases in pancreatic cells under the kidney capsule of immunodeficient mice together with human fetal pancreatic cells, plasma human C-peptide and the largest decreases in blood glucose. This observation is similar to the rela-suggesting that β-cell precursors in the adult human pancreas had responded to inductive cues in the fetal tionship between pancreatic β-cell mass and blood glucose levels in humans (21) , and suggests that only par-pancreas, possibly mimicking the process of β-cell neogenesis during gestation (13). In another recent study, tial regeneration of the pancreatic β-cell mass may be sufficient to restore normoglycemia.
affinity-purified human pancreatic duct cells were reported to differentiate to β-cells; however, only approxi-β-Cells have been generated in vitro by culture of both adult rodent (19, 23) and human (1, 11, 12) pancre-mately 1% of duct cells expressed insulin, even after implantation in normoglycemic NOD-scid mice (37) . atic tissue enriched for duct cells. In one study, adult human pancreatic cultures formed clusters and cysts
In a previous study, we found that the combination of EGF and gastrin increased the β-cell mass in adult containing cells comprised mostly of CK19-positive duct cells along with cells immunoreactive for insulin human pancreatic cell preparations in vitro (29) . EGF stimulated the proliferation of CK19-positive duct cells and other islet hormones (1) . In other studies, adult human pancreatic cultures contained proliferating CK19-and gastrin was required to induce expression of PDX-1 in the duct cells and their differentiation into insulin-positive duct cells that reexpressed the pancreatic and duodenal homeobox transcription factor-1, PDX-1 (12) expressing cells (29) . In the present study, we substituted GLP-1 for EGF in combination with gastrin because and differentiated into endocrine cells (11). In a subse- 
